神州细胞(688520) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for the third quarter was ¥339,860,646.36, a decrease of 46.25% compared to the same period last year[3]. - The total profit for the third quarter was -¥217,421,450.38, with a year-to-date total profit of -¥251,279,601.67[3]. - The net profit attributable to shareholders for the third quarter was -¥216,901,236.46, and -¥250,672,332.75 year-to-date[3]. - Total operating revenue for the first three quarters of 2025 was approximately ¥1.31 billion, a decrease of 32.3% compared to ¥1.94 billion in the same period of 2024[16]. - Net profit for the first three quarters of 2025 was a loss of approximately ¥251.28 million, compared to a profit of ¥150.41 million in 2024[17]. - The company recorded a total comprehensive loss of approximately ¥251.19 million in 2025, compared to a total comprehensive income of ¥150.44 million in 2024[17]. Research and Development - Research and development expenses totaled ¥203,990,325.36 for the quarter, accounting for 60.02% of operating revenue, an increase of 25.99 percentage points[4]. - Research and development expenses for the first three quarters of 2025 were approximately ¥581.82 million, a decrease of 13.3% from ¥671.79 million in 2024[16]. Assets and Liabilities - Total assets increased to ¥3,761,436,578.09, representing a 14.54% increase from the end of the previous year[4]. - The company's current assets totaled CNY 1,826,472,317.93, up from CNY 1,460,622,848.37 in the previous period, reflecting a growth of approximately 25.1%[12][13]. - Total liabilities reached CNY 3,816,211,088.58, compared to CNY 3,149,055,574.41, reflecting an increase of approximately 21.2%[14]. - The company's short-term borrowings surged to CNY 1,762,437,408.90 from CNY 1,077,987,553.63, a significant increase of about 63.5%[13][14]. - The total equity attributable to shareholders decreased to CNY -48,211,427.97 from CNY 140,896,888.73, indicating a decline in shareholder equity[14]. - The total liabilities to equity ratio has increased, indicating a higher leverage position for the company compared to the previous period[14]. Cash Flow - The cash flow from operating activities for the year-to-date was -¥306,820,436.08[4]. - The company reported a net cash outflow from operating activities of approximately ¥306.82 million in 2025, down from a cash inflow of ¥189.69 million in 2024[19]. - Cash inflow from investment activities was approximately ¥1.13 billion in 2025, compared to ¥752.09 million in 2024[19]. - Net cash inflow from financing activities was approximately ¥736.77 million in 2025, significantly higher than ¥159.75 million in 2024[20]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 13,749[9]. - The largest shareholder, Lhasa Ailike Investment Consulting Co., Ltd., held 60.90% of the shares[9]. Earnings Per Share - The company reported a basic earnings per share of -¥0.50 for the third quarter and -¥0.60 year-to-date[3]. - Basic and diluted earnings per share for the first three quarters of 2025 were both -¥0.60, compared to ¥0.34 in 2024[17]. Sales and Revenue Decline - The company experienced a decline in sales revenue due to price reductions of its core product, Anjiajin®[7]. - Total operating costs increased to approximately ¥1.49 billion in 2025, up 2.2% from ¥1.46 billion in 2024[16]. Cash and Cash Equivalents - Cash and cash equivalents increased to CNY 396,498,224.09 from CNY 314,933,923.79, representing a rise of about 26%[12]. - Cash and cash equivalents at the end of the third quarter of 2025 totaled approximately ¥396.50 million, an increase from ¥340.44 million at the end of the same period in 2024[20]. Inventory and Accounts Receivable - Accounts receivable rose to CNY 688,905,342.85, compared to CNY 649,386,298.44, indicating an increase of approximately 6.1%[12]. - Inventory levels increased to CNY 326,970,398.21 from CNY 259,486,715.96, marking a growth of around 26%[12][13]. Non-Current Assets - The company reported a total non-current asset value of CNY 1,934,964,260.16, up from CNY 1,823,373,569.25, showing an increase of approximately 6.1%[13].